Fosinopril
drugOn this page
Also known as C09AA09Fosenopril
Summary
Fosinopril (CHEMBL3039598) is an approved small molecule (ATC C09AA09) targeting ACE; indicated across 4 conditions including cardiovascular disorder and diabetic kidney disease.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: C09AA09
- Targets: 1 (ACE)
- Indications: 4 conditions
- Clinical trials: 7
- Chemistry: 563.7 Da · C30H46NO7P
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL3039598 |
| Name | Fosinopril |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 9601226 |
| ATC | C09AA09 |
| Molecular formula | C30H46NO7P |
| Molecular weight | 563.7 |
| InChIKey | BIDNLKIUORFRQP-XYGFDPSESA-N |
SMILES: CCC(=O)O[C@H](C(C)C)O[P@](=O)(CCCCC1=CC=CC=C1)CC(=O)N2C[C@@H](C[C@H]2C(=O)O)C3CCCCC3
IUPAC name: (2S,4S)-4-cyclohexyl-1-[2-[[(1S)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid
Also known as: C09AA09, Fosenopril, Fosinopril, fosinopril, FOSINOPRIL
Parent form; salt/anhydrous children: CHEMBL3039596
Patent coverage: 19 distinct patent families (61 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| ACE | Angiotensin-converting enzyme | Inhibition | 0.7% | P12821 |
Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Angiotensin-converting enzyme, D(1A) dopamine receptor, Bile salt export pump.
Bioactivity
ChEMBL activities: 1 potent at pChembl ≥ 5 of 3 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| ACE | 9 | IC50 | 1 | nM | CHEMBL_ACT_660927 |
Target pathways
Aggregated over 1 target gene(s): ACE.
Top Reactome pathways
3 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| Metabolism of Angiotensinogen to Angiotensins | 1 | ACE |
| Peptide hormone metabolism | 1 | ACE |
| Metabolism of proteins | 1 | ACE |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| kidney development | 1 |
| blood vessel remodeling | 1 |
| angiotensin maturation | 1 |
| regulation of renal output by angiotensin | 1 |
| neutrophil mediated immunity | 1 |
| antigen processing and presentation of peptide antigen via MHC class I | 1 |
| regulation of systemic arterial blood pressure by renin-angiotensin | 1 |
| positive regulation of systemic arterial blood pressure | 1 |
| proteolysis | 1 |
| spermatogenesis | 1 |
| regulation of blood pressure | 1 |
| male gonad development | 1 |
| post-transcriptional regulation of gene expression | 1 |
| negative regulation of gene expression | 1 |
| substance P catabolic process | 1 |
Indications & clinical
Indications
4 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| cardiovascular disorder | 4 | MONDO:0004995 | EFO:0000319 |
| diabetic kidney disease | 2 | MONDO:0005016 | EFO:0000401 |
| hypertensive disorder | 2 | MONDO:0005044 | EFO:0000537 |
| heart disorder | 2 | MONDO:0005267 | EFO:0003777 |
Clinical trials
Total trials: 7.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 2 |
| PHASE2 | 2 |
| Not specified | 2 |
| PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01014338 | PHASE4 | COMPLETED | Angiotensin-converting Enzyme (ACE)-Inhibition and Mechanisms of Skeletal Muscle Weakness in Chronic Obstructive Pulmonary Disease (COPD) |
| NCT02646397 | PHASE4 | UNKNOWN | Benidipine and Hydrochlorothiazide in Fosinopril Treated Chronic Kidney Disease Patients With Hypertension |
| NCT03073018 | PHASE3 | COMPLETED | Prevention of Renal and Vascular Endstage Disease Intervention Trial |
| NCT00051389 | PHASE2 | COMPLETED | ACE Inhibition and Novel Cardiovascular Risk Factors |
| NCT00315016 | PHASE2 | COMPLETED | Eplerenone, ACE Inhibition and Albuminuria |
| NCT00565396 | Not specified | UNKNOWN | Effectiveness Study on Fosinopril and/or Losartan in Patients With Chronic Kidney Disease Stage 3 |
| NCT01342614 | Not specified | COMPLETED | The Effect of Metformin on the Correlation Between Hyperinsulinemia and Hypertension |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.
32 molecules share ≥1 primary target. Top 32 by shared-target count:
| Molecule | Source | Status | Shared targets |
|---|---|---|---|
| CAPTOPRIL | ChEMBL + PubChem | Phase 4 (approved) | ACE |
| LOSARTAN | ChEMBL + PubChem | Phase 4 (approved) | ACE |
| PERINDOPRIL | ChEMBL + PubChem | Phase 4 (approved) | ACE |
| SITAGLIPTIN | ChEMBL + PubChem | Phase 4 (approved) | ACE |
| BENAZEPRIL | ChEMBL | Phase 4 (approved) | ACE |
| ENALAPRIL | ChEMBL | Phase 4 (approved) | ACE |
| ENALAPRILAT | ChEMBL | Phase 4 (approved) | ACE |
| IMIDAPRIL | ChEMBL | Phase 4 (approved) | ACE |
| LISINOPRIL | ChEMBL | Phase 4 (approved) | ACE |
| MOEXIPRIL | ChEMBL | Phase 4 (approved) | ACE |
| QUINAPRIL | ChEMBL | Phase 4 (approved) | ACE |
| RAMIPRIL | ChEMBL | Phase 4 (approved) | ACE |
| TELMISARTAN | ChEMBL | Phase 4 (approved) | ACE |
| TRANDOLAPRIL | ChEMBL | Phase 4 (approved) | ACE |
| EDETIC ACID | ChEMBL | Phase 3 | ACE |
| QUINAPRILAT | ChEMBL + PubChem | Phase 2 (approved) | ACE |
| BENAZEPRILAT | ChEMBL | Phase 2 | ACE |
| CERONAPRIL | ChEMBL | Phase 2 | ACE |
| FOSINOPRILAT | ChEMBL | Phase 2 | ACE |
| IMIDAPRILAT | ChEMBL | Phase 2 | ACE |
| LIBENZAPRIL | ChEMBL | Phase 2 | ACE |
| MOEXIPRILAT | ChEMBL | Phase 2 | ACE |
| OMAPATRILAT | ChEMBL | Phase 2 | ACE |
| PROLINE | ChEMBL | Phase 2 | ACE |
| RENTIAPRIL | ChEMBL | Phase 2 | ACE |
| SAMPATRILAT | ChEMBL | Phase 2 | ACE |
| SPIRAPRILAT | ChEMBL | Phase 2 | ACE |
| TEPROTIDE | ChEMBL | Phase 2 | ACE |
| ZOFENOPRIL | ChEMBL | Phase 2 | ACE |
| Gallic Acid | PubChem | Approved | ACE |
| Hydrochlorothiazide | PubChem | Approved | ACE |
| Paclitaxel | PubChem | Approved | ACE |
Related Atlas pages
- Genes: ACE
- Diseases: cardiovascular disorder
- Drugs: Captopril, Losartan, Perindopril, Sitagliptin, Benazepril, Enalapril, Enalaprilat, Imidapril, Lisinopril, Moexipril, Quinapril, Ramipril, Telmisartan, Trandolapril, Edetic Acid, Hydrochlorothiazide, Paclitaxel